Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerPersistent high risk HPV infection associated with development of cervical neoplasia in a prospective population studyAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.AACR Cancer Progress Report 2014Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study.Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women.Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method.Semantic focusing allows fully automated single-layer slide scanning of cervical cytology slidesValidation of human papillomavirus genotyping by signature DNA sequence analysis.The status of cervical cytology in Swaziland, Southern Africa: a descriptive study.A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.Cervical cancer: Can it be prevented?Evaluation of transported dry and wet cervical exfoliated samples for detection of human papillomavirus infection.Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus.Association between physician specialty and uptake of new medical technologies: HPV tests in Florida Medicaid.Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologiesOncogenic human papillomavirus genital infection in southern Iranian women: population-based study versus clinic-based dataInformatics methods for laboratory evaluation of HPV ordering patterns with an example from a nationwide sample in the United States, 2003-2009.HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.Scientific issues related to the cytology proficiency testing regulations.Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device.Health and economic implications of HPV vaccination in the United States.Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practiceAsia oceania guidelines for the implementation of programs for cervical cancer prevention and control.Human papillomavirus detection in cervical scrapes from women attended in the Family Health ProgramCost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive womenSwitch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia.Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study.Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology.Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancerEffects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA testsAge-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopyCervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practicePrimary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring.
P2860
Q24607403-CCEBD404-0F23-46E3-980C-B689B6788611Q24672296-88B4CC89-9DC1-4F2C-A2B7-642F2BCE6CB4Q26828840-E89DD79D-9436-4332-8D0B-D736265409F3Q27346723-F822B2F1-5AB2-45F1-AE0B-AE655E85FCDDQ30440400-9AA63F8B-3BDF-471A-ABE0-3EF31B34AF7BQ30712681-35CC2127-3C9A-422F-BD8D-C6BCAF0C4F51Q31075135-C101B719-E3D7-4A81-A21D-A356EC79C2D1Q31115232-19DB2326-1617-4205-AB82-A4BAE61463BDQ33450984-81D91962-190C-4C6D-B7F1-281C4017B6E2Q33510336-6E23A125-EEDD-4E92-B44A-477F84BB79E1Q33545461-39A31B0D-28CC-47F1-91CC-62A8255B5322Q33746081-C728F49A-4093-4B37-83C5-35A8C64DC0B6Q34031277-619A1FA4-7729-4449-9A00-8BE42AB14D2AQ34120314-A893E02F-8856-4486-8B2C-6FEC7FF4AC04Q34159707-6C1B2721-C569-4B32-A444-DC8CE8749CCBQ34164287-65E1467B-FA34-4310-9381-06275DC9EA90Q34250191-AC8D3D31-2D40-417B-977A-7A9BAB9AF349Q34330297-B70683F6-FBEF-4805-BFA8-E9EA140B4FE5Q34411356-8695DAC9-4E77-423A-8FD2-59D45A04F966Q34442449-9C277843-C318-49A4-8EB8-022D25294D54Q34511387-F35A036D-ED23-40D0-B63C-97BEC9C32751Q34690621-796155A5-0CB7-4C4B-ACB1-73A91A8BC7C9Q34719617-191C70CB-0ABD-4E04-8444-D2243EC0B3BBQ34824304-1792A1E4-27F1-4292-B7B9-1F937AB89AD2Q34850316-2A341404-9832-4678-A7E3-2536E03E3EB6Q34866621-FE628298-7724-4EF2-B27B-37F6DBEF1E1FQ34936354-0678CDF0-3367-4B8A-A314-5095A3D1725FQ34997604-A6703708-B87C-46AB-A004-EB3B347230E8Q35051454-AF23981E-2DA8-4826-8994-135D00A31606Q35125113-B166F38F-64F8-4A02-98F1-24E2AC79652BQ35182177-72D9A045-A628-48C2-BE38-5D03311CB3F9Q35203251-6AF5EBBC-E9DD-49DF-80CB-C3E995C82DBAQ35212627-28407101-D09E-4CE9-AB67-DF5B75FDBB16Q35220798-6E773123-4154-46E4-80AC-DA558E1561DDQ35287748-65F2D2DD-8714-485B-8DE6-A2A5ED5DB1FCQ35508095-07D8592B-8FD4-49CD-86C9-DA2BE0CE21DAQ35699092-7F4F3273-85D1-4A88-80DC-B674B0E97980Q35738881-15253970-DD58-4293-BA79-3F53F8B786FBQ35802505-CB41F9A5-418B-4400-A3AD-B15AC710BD00Q35802914-55B8A904-C7B3-48A9-AD76-B558FCEE48C0
P2860
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Interim guidance for the use o ...... rvical cytology for screening.
@ast
Interim guidance for the use o ...... rvical cytology for screening.
@en
type
label
Interim guidance for the use o ...... rvical cytology for screening.
@ast
Interim guidance for the use o ...... rvical cytology for screening.
@en
prefLabel
Interim guidance for the use o ...... rvical cytology for screening.
@ast
Interim guidance for the use o ...... rvical cytology for screening.
@en
P2093
P1476
Interim guidance for the use o ...... rvical cytology for screening.
@en
P2093
Carolyn Runowicz
Debbie Saslow
Diane Solomon
Francisco Garcia
J Thomas Cox
Kenneth Hatch
Kenneth L Noller
Nancy Roach
Thomas C Wright
P304
P356
10.1097/01.AOG.0000109426.82624.F8
P407
P577
2004-02-01T00:00:00Z